A Durable Response after the Discontinuation of Nivolumab in an Advanced Gastric Cancer Patient

A durable response after the discontinuation of immune checkpoint-inhibitor therapy has previously been reported in several cancers. We herein describe a patient with gastric cancer who maintained nivolumab. 65-year-old man was treated nivolumab as sixth-line for recurrent cancer. After four cycles therapy, he showed partial response. But treatment discontinued when two immune-related adverse events occurred six cycles. Disease regression sustained approximately 2 years, without re-administration The characteristics leading to such responses are unclear, and further studies warranted this regard.